Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study)

Exclusion Criteria

• •Other major or clinically uncontrolled diseases
• •Pregnancy or breastfeeding
• •History of allergy to any component of the study medication
• •Positivity for HBV surface antigen at the screening visit
• •Positivity for HCV serology at the screening visit
• •Active tuberculosis or inadequately treated history of tuberculosis
• •Significant abnormalities in electrocardiogram at the screening visit
• •Clinically significant abnormalities of the X-ray chest at the screening visit
• •History of HIV infection or other acquired or congenital immunodeficiencies
• •Active abuse or history of substance abuse 6 months prior to the screening visit
• •Bacterial infection that required oral or injectable antibiotics or important viral or fungal infections within 4 weeks prior to the screening visit
• •Malignancy or history of malignancy (other than cured in situ cutaneous squamous cell carcinoma or basal cell carcinoma, or in situ cérvix carcinoma without evidence of recurrence in the last 5 years)
• •Rebound or relapse of psoriasis in the 4 weeks prior to the screening visit
• •Presence of other cutaneous diseases that could interfere in the clinical assessment of the study
• •Use of topical treatments that include corticosteroids, salicylic acid, urea\> 10% or calcipotriol in the 2 weeks prior to the screening visit
• •Use of systemic treatments for psoriasis, including systemic corticosteroids and PUVA or UVB phototherapy, within 4 weeks prior to the screening visit
• •Previous or current use of biological treatments
• •Use of any investigational drug within 4 weeks prior to the screening visit
• •Previous treatment with apremilast